Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medication is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medication should be based on the patient's current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no prior antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions, 2. Contraindications).
2. Patients receiving metformin:
- For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose.
- Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin.
3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medication. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed.
Patients with renal impairment
This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment.
Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
Patients with hepatic impairment
This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Contraindications).
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication helps control blood glucose levels in patients with type 2 diabetes when used alongside dietary and exercise therapy. Sitagliptin and Metformin work together to effectively improve blood glucose levels. This can facilitate easier blood sugar management and help in preventing complications. Continuing to take this medication may assist in maintaining a healthy blood glucose state.
How to take
Adult dose
For antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
This medication is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
The initial dose of this medication should be based on the patient's current treatment regimen.
1. Patients not currently receiving metformin:
For patients with no prior antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions, 2. Contraindications).
2. Patients receiving metformin:
- For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose.
- Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin.
3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined by taking the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions).
No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medication. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed.
Patients with renal impairment
This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment.
Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately.
Patients with hepatic impairment
This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Contraindications).
Precautions
This medication is used for the treatment of diabetes and contains two components. The first component helps regulate blood glucose levels, but in some patients, serious allergic reactions may occur, and caution should be exercised. Such allergic reactions are most likely to occur within the first 3 months after taking the medication, and if symptoms are suspected, the medication should be stopped immediately, and a doctor should be consulted.
Additionally, this medication can induce pancreatitis, a serious inflammation of the pancreas, so if symptoms such as abdominal pain or vomiting occur during treatment, it should be reported to healthcare professionals immediately. The second component carries a risk of lactic acidosis, a rare but potentially fatal metabolic disorder, and should not be administered to patients with impaired kidney function, severe infections, or dehydration.
This medication should not be used in patients with moderately impaired kidney function or higher, those with acute heart failure or myocardial infarction, pregnant or breastfeeding women, and patients with certain acute conditions. Regular monitoring of kidney function and blood tests should be conducted during treatment for adverse symptoms.
During treatment, symptoms of hypoglycemia may occur if blood sugar levels drop too low, so particular care should be taken with irregular eating or vigorous exercise. The risk of hypoglycemia may increase when used with other blood sugar-lowering agents; hence, medication doses should be adjusted according to a doctor’s directions.
Taking this medication with alcohol may increase risks, so excessive drinking should be avoided. In the case of scheduled surgeries or tests using iodinated contrast agents, this medication should be temporarily discontinued for a period, and it should be readministered only after confirming normal kidney function.
If symptoms such as skin rash, hives, difficulty breathing, severe joint pain, or bullous skin disorders occur after taking the medication, inform a doctor immediately and stop the medication. Elderly patients may have a higher likelihood of decreased renal function, so doses should be adjusted with greater caution and their condition should be monitored regularly.
Finally, this medication is not recommended for use in children under 18 as safety and efficacy have not been sufficiently confirmed.
Side effects
Anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory infection
headache
nausea
Show 22 moreCollapse
vomiting
abdominal pain
nasopharyngitis
constipation
severe and disabling arthralgia
vesicular pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
rhabdomyolysis
dyspnea
unstable angina
dizziness
acute renal failure
decreased appetite
itching
dermatitis
anorexia
weight loss
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, and it is best kept at room temperature between 1 and 30 degrees Celsius.
Storing it this way can help maintain the drug's effectiveness for a longer period.
Appearance and packaging
Appearance
Light pink oval film-coated tablet
Package unit
60 tablets/box [(10 tablets/PTP X 6)]
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.